Mary Mazer
Family · San Antonio, TXNPI 1083982383
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,923 of the $4,438 with a category attached, or 88.4%. It is spread thinly across 36 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,913, 4.1 times the $469 reported in 2021. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $27.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$534
- AstraZeneca$440
- Seagen Inc.$432
- Gilead$313
- Novartis$273
- Lilly USA, LLC$258
- plus $2K from 30 others
What the payments were for
- Consulting fees$3257%
- Food & beverage$3,92388%
- Education$1904%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 16 | $534 |
| AstraZeneca | 19 | $440 |
| Seagen Inc. | 3 | $432 |
| Gilead | 14 | $313 |
| Novartis | 13 | $273 |
| Lilly USA, LLC | 15 | $258 |
| Incyte Corporation | 7 | $228 |
| Genentech USA, Inc. | 12 | $224 |
| Johnson & Johnson | 4 | $174 |
| Amgen | 7 | $158 |
| Puma Biotechnology, Inc. | 3 | $153 |
| Pharmacosmos Therapeutics Inc. | 1 | $125 |
| Merck | 6 | $115 |
| Genentech, Inc. | 1 | $113 |
| AVEO Pharmaceuticals, Inc. | 4 | $86 |
| Sanofi | 4 | $85 |
| Pfizer | 4 | $77 |
| Stemline Therapeutics Inc. | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Bristol Myers Squibb | 2 | $52 |
| Genmab U.S., Inc. | 2 | $50 |
| Sobi, Inc | 2 | $46 |
| Karyopharm Therapeutics Inc. | 2 | $44 |
| GSK | 2 | $42 |
| Tersera Therapeutics LLC | 2 | $39 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Fresenius Kabi USA, LLC | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 1 | $27 |
| Legend Biotech USA Inc. | 1 | $26 |
| Morphosys, US Inc. | 1 | $25 |
| Spectrum Pharmaceuticals Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Macrogenics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,438 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamoxifen Citrate | 12 | $391 |
| Anastrozole | 15 | $248 |
Paid to pharmacies, not to this prescriber.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Febbie PhiriSan Antonio$31K
- Annette GantzSan Antonio$31K
- Renee ChisumSan Antonio$28K
- Thimios PartalasSan Antonio$27K
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.